Exscientia Future Growth
Future criteria checks 1/6
Exscientia's earnings are forecast to decline at 13% per annum while its annual revenue is expected to grow at 19% per year. EPS is expected to decline by 6.4% per annum. Return on equity is forecast to be -80.7% in 3 years.
Key information
-13.0%
Earnings growth rate
-6.4%
EPS growth rate
| Biotechs earnings growth | 21.3% |
| Revenue growth rate | 19.0% |
| Future return on equity | -80.7% |
| Analyst coverage | Low |
| Last updated | 17 Apr 2024 |
Recent future growth updates
Recent updates
Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11
Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 35 | N/A | N/A | N/A | 1 |
| 12/31/2025 | 49 | -192 | N/A | N/A | 3 |
| 12/31/2024 | 58 | -186 | N/A | N/A | 3 |
| 12/31/2023 | 20 | -146 | -144 | -118 | N/A |
| 9/30/2023 | 24 | -144 | -195 | -166 | N/A |
| 6/30/2023 | 22 | -148 | -205 | -173 | N/A |
| 3/31/2023 | 26 | -141 | -119 | -88 | N/A |
| 12/31/2022 | 27 | -119 | -83 | -61 | N/A |
| 9/30/2022 | 25 | -100 | -46 | -28 | N/A |
| 6/30/2022 | 36 | -69 | 3 | 17 | N/A |
| 3/31/2022 | 29 | -59 | -23 | -13 | N/A |
| 12/31/2021 | 27 | -49 | -14 | -7 | N/A |
| 9/30/2021 | 27 | -36 | -7 | 0 | N/A |
| 6/30/2021 | 10 | -39 | -15 | -11 | N/A |
| 3/31/2021 | 13 | -24 | -31 | -27 | N/A |
| 12/31/2020 | 10 | -22 | -24 | -21 | N/A |
| 12/31/2019 | 9 | -6 | 5 | 7 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: EXAI is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: EXAI is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: EXAI is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: EXAI's revenue (19% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: EXAI's revenue (19% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: EXAI is forecast to be unprofitable in 3 years.